FMR1 and fragile X syndrome: Noteworthy, MIA-treatment in Fmr1 KO animals did not exacerbate the pre-existing altered activity of S6K1 and rpS6 (Fig. 4i–l), supporting the lack of synergistic effects of MIA in FXS.